Flexion Therapeutics, Inc. (NASDAQ:FLXN)‘s stock had its “buy” rating reiterated by equities researchers at Needham & Company LLC in a note issued to investors on Sunday. They currently have a $36.00 price target on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective points to a potential upside of 49.25% from the stock’s previous close.

A number of other analysts have also weighed in on the stock. Royal Bank Of Canada set a $44.00 price objective on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research note on Monday, September 11th. ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Zacks Investment Research upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. Northland Securities assumed coverage on shares of Flexion Therapeutics in a research note on Thursday, August 24th. They issued an “outperform” rating and a $40.00 price objective on the stock. Finally, BMO Capital Markets reiterated a “buy” rating on shares of Flexion Therapeutics in a research note on Friday, August 11th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $31.50.

Flexion Therapeutics (NASDAQ FLXN) opened at 24.12 on Friday. The stock’s market cap is $769.55 million. The stock’s 50 day moving average is $23.25 and its 200 day moving average is $22.01. Flexion Therapeutics has a 52 week low of $15.93 and a 52 week high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11). Analysts predict that Flexion Therapeutics will post ($3.70) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/17/flexion-therapeutics-inc-flxn-given-buy-rating-at-needham-company-llc.html.

In other news, insider Yamo Deniz purchased 3,000 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were purchased at an average cost of $24.15 per share, with a total value of $72,450.00. Following the completion of the acquisition, the insider now owns 5,000 shares of the company’s stock, valued at approximately $120,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have purchased 5,375 shares of company stock worth $131,575 over the last three months. 15.98% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fiduciary Trust Co. purchased a new stake in Flexion Therapeutics during the second quarter worth $101,000. IFP Advisors Inc boosted its holdings in Flexion Therapeutics by 24.5% during the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 1,000 shares in the last quarter. Advisor Group Inc. boosted its holdings in Flexion Therapeutics by 205.9% during the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 3,500 shares in the last quarter. Voya Investment Management LLC boosted its holdings in Flexion Therapeutics by 25.8% during the second quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock worth $261,000 after buying an additional 2,651 shares in the last quarter. Finally, BB&T Securities LLC purchased a new stake in Flexion Therapeutics during the second quarter worth $289,000. 82.75% of the stock is currently owned by hedge funds and other institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.